Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.